- Home
- SNES vs ENVB Comparison
SNES vs ENVB Comparison
Compare SNES & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | ENVB |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.1M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SNES | ENVB |
|---|---|---|
| Price | $1.38 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 132.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.99 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $600,000.00 | ★ $39,914,675.00 |
| Revenue This Year | $29.00 | N/A |
| Revenue Next Year | $95.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.56 | N/A |
| 52 Week Low | $1.37 | $0.56 |
| 52 Week High | $5.99 | $13.25 |
Technical Indicators
Market Signals| Indicator | SNES | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 36.40 |
| Support Level | N/A | $0.60 |
| Resistance Level | $1.76 | $1.58 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 2.94 | 35.19 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.